Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Erlotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 15/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 1.00 |
| ▸ | GAK | O14976 | 3/20 | 0.98 |
| ▸ | ILK | Q13418 | 3/20 | 0.98 |
| ▸ | FLT1 | P17948 | 2/20 | 0.98 |
| ▸ | KDR | P35968 | 2/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
| ▸ | AURKA | O14965 | 1/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | BUB1 | O43683 | 1/20 | 0.98 |
| ▸ | KDM1A | O60341 | 1/20 | 0.98 |
| ▸ | JAK2 | O60674 | 1/20 | 0.98 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.98 |
| ▸ | STK17B | O94768 | 1/20 | 0.98 |
| ▸ | STK10 | O94804 | 1/20 | 0.98 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erlotinib SCHEMBL18563 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL16767632 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL29460839 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL3826918 | 0.99 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL1759094 | 0.99 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL29351329 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL30362833 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL8413 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL3667407 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL1959332 | 0.98 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115381826-A | Medicine for treating tumor | 正大天晴药业集团股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-114984204-A | Combined medicine for treating tumor | 正大天晴药业集团股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112839947-A | TLR7 agonist for treating colorectal cancer and pharmaceutical composition thereof | 正大天晴药业集团股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-112105620-A | TLR7 agonist for treating lung cancer and pharmaceutical composition thereof | 正大天晴药业集团股份有限公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2019141170-A1 | APPLICATION OF NOVEL TYROSINE KINASE INHIBITOR, ANLOTINIB, IN OSTEOSARCOMA AND CHONDROSARCOMA | 正大天晴药业集团股份有限公司 | 2019-07-25 | — | — | WO | disclosed |